Peptide YY Protocol: Complete Cycling & Dosing Guide

Peptide YY Protocol: Complete Cycling & Dosing Guide

Overview

Peptide YY 3-36 (PYY) is a truncated gut hormone naturally released from intestinal L-cells in response to caloric intake. As a selective agonist at the neuropeptide Y2 receptor (NPY2R), it functions as a potent appetite suppressant by inhibiting hunger-promoting neurons in the hypothalamic arcuate nucleus while simultaneously slowing gastric emptying and reducing gut motility. The result is significant suppression of food intake lasting several hours post-administration.

Unlike anabolic compounds, PYY is primarily investigated for appetite control and weight management in both lean and obese populations. It carries a generally acceptable short-term safety profile in controlled settings, though nausea remains the primary dose-limiting side effect. Importantly, PYY is not FDA or EMA approved and exists only as a research compound. Self-administration carries risks including uncontrolled caloric restriction, unknown long-term endocrine effects, and variable purity from research vendors.

Available routes include subcutaneous injection (200–600 mcg once daily) and nasal administration (200–400 mcg once daily), with monthly costs ranging $60–$200 depending on vendor and formulation.

Standard Protocol

Route Selection

Begin by choosing your administration route:

• Subcutaneous Injection: More predictable pharmacokinetics and dose delivery; preferred for protocol consistency. Inject into subcutaneous tissue of abdomen, thigh, or upper arm. Rotate injection sites to minimize tissue irritation.
• Nasal: Non-invasive alternative with lower peak doses required, though absorption variability is higher. Better suited for users averse to needles.

Baseline Dosing (Injection)

Start at 200 mcg once daily for the first 1–2 weeks. This minimizes nausea risk and allows your body to acclimate to appetite suppression. Administer at the same time each day, preferably in the morning before breakfast.

Titration Schedule

Week 1–2: 200 mcg daily Week 3–4: 300 mcg daily (if well-tolerated) Week 5+: 400–600 mcg daily (based on appetite response and side effect tolerance)

Do not exceed 600 mcg daily from a single injection; if higher doses are needed, split into two administrations or switch to nasal route.

Nasal Protocol

Start at 200 mcg once daily. Titrate by 100 mcg increments every 2–3 weeks up to 400 mcg maximum. Nasal delivery typically requires lower total daily doses due to direct CNS access via the nasal epithelium.

Standard Cycle Length

Use PYY in 8–12 week on-cycles, followed by 4 week off-cycles. This pattern:

• Preserves receptor sensitivity and prevents downregulation
• Allows endogenous appetite hormone production to normalize
• Reduces potential long-term safety risks from continuous administration
• Maintains efficacy across multiple cycles

Typical user reports: maximal appetite suppression occurs weeks 2–8, with diminishing returns by week 10–12.

Daily Timing

Inject or administer intranasally 30–60 minutes before breakfast. PYY peak effect occurs 15–30 minutes post-administration and persists 3–6 hours. This timing maximizes suppression of the largest meal window and prevents late-day hunger rebounds.

Goal-Specific Protocols

Fat Loss Protocol (Appetite Suppression)

This is PYY's primary application. Structure the cycle to sustain consistent appetite reduction throughout the dieting phase.

• Weeks 1–2: 200 mcg daily (tolerance phase)
• Weeks 3–12: 400–500 mcg daily (maintenance phase)
• Off-cycle: 4 weeks

Pair with a moderate caloric deficit (300–500 kcal below maintenance) and high protein intake (1.0–1.2 g per lb bodyweight). PYY suppresses hunger but does not prevent intentional undereating; monitor energy levels and cease if fatigue becomes pronounced.

Expected fat loss: 0.5–2 lbs per week depending on baseline weight, deficit magnitude, and training. PYY effectiveness is greatest in obese individuals; lean users may see diminished appetite suppression.

Refractory Period Management

Some users report reduced appetite suppression by week 10–12 despite consistent dosing. This suggests receptor desensitization. Strategies:

1. Extend the off-cycle to 6–8 weeks before restarting
2. Rotate between injection and nasal routes during the second cycle
3. Stack with a complementary appetite suppressant (see stacking section) during the final 4–6 weeks of the cycle

Hormonal Balance Protocol

PYY naturally increases with dietary fiber, propionate supplementation (10 g/day inulin-propionate ester), and specific macronutrient profiles. Rather than exogenous PYY, consider elevating endogenous PYY first:

• Increase soluble fiber to 15–25 g daily
• Add propionate-ester supplement for 8–12 weeks
• Consume wholemeal grains (increase postprandial PYY by ~44% vs. refined grains)
• Include high-protein meals (protein stimulates PYY release)

If exogenous PYY is still desired, use the standard fat loss protocol above (weeks 1–12, 200–500 mcg daily).

How to Administer Step-by-Step

Subcutaneous Injection

1. Reconstitution (if lyophilized): Draw 0.5–1.0 mL bacteriostatic water (0.9% sodium chloride + 0.9% benzyl alcohol) into an insulin syringe. Inject slowly into the vial containing lyophilized PYY. Allow 2–3 minutes for complete dissolution. Do not shake vigorously, as this degrades the peptide.

2. Preparation: Store reconstituted solution at 2–8°C (refrigerated) for up to 2 weeks. Pre-draw your daily dose into a separate insulin syringe 1–2 hours before administration to allow the peptide to reach ambient temperature, improving absorption.

3. Site Selection: Rotate between abdomen, outer thigh, and upper arm. Avoid the same site for consecutive injections.

4. Administration: Pinch the skin to create a fold. Insert the needle at a 45–90° angle into subcutaneous tissue (not muscle). Depress the plunger fully and withdraw the needle. Apply light pressure with a sterile pad for 10 seconds if bleeding occurs.

5. Timing: Administer 30–60 minutes before your first meal to maximize appetite suppression during the largest eating window.

Nasal Administration

1. Preparation: If using powder, reconstitute with sterile saline (0.9% NaCl) to desired concentration (typically 100 mcg/spray). Mix gently by rolling the vial between your palms; avoid vigorous shaking.

2. Delivery: Use a metered nasal spray bottle. Tilt your head back slightly, insert the nozzle into one nostril, and depress firmly to deliver one spray. Sniff gently to distribute the peptide through nasal mucosa. Repeat in the contralateral nostril if higher doses are required.

3. Timing: Administer 30–60 minutes before breakfast, same as injection.

Cycle Example (Week-by-Week Schedule)

12-Week Cycle with 4-Week Off-Phase

Phase 1: Titration (Weeks 1–4)

• Week 1: 200 mcg daily, subcutaneous injection, morning pre-breakfast
• Week 2: 200 mcg daily
• Week 3: 300 mcg daily (increase by 100 mcg)
• Week 4: 300 mcg daily

Assessment: Evaluate appetite suppression and nausea severity. If nausea is minimal and appetite reduction is substantial, proceed to full dose. If nausea persists, remain at 300 mcg for an additional 2 weeks.

Phase 2: Maintenance (Weeks 5–12)

• Weeks 5–12: 400–500 mcg daily, same injection site rotation and timing

Appetite Suppression Monitoring: Track food intake, hunger ratings (1–10 scale), and energy levels daily. Peak suppression occurs weeks 6–8. If suppression diminishes by week 10, consider extending the off-cycle or rotating administration routes in the next cycle.

Phase 3: Off-Cycle (Weeks 13–16)

• Complete cessation of PYY administration
• Allow endogenous appetite hormone production to normalize
• Expect mild appetite rebound in days 1–3; this is normal and will resolve
• Monitor for return of normal hunger cues by week 3–4

Subsequent Cycles: Begin cycle 2 at week 17 with the same titration schedule (weeks 1–4 at 200–300 mcg, weeks 5–12 at 400–500 mcg).

What to Expect (Timeline of Effects)

Days 1–3

• Mild nausea in 20–30% of users (most common side effect)
• Reduced appetite, particularly for large meals
• Possible mild dizziness or lightheadedness, secondary to reduced caloric intake

Week 1–2

• Nausea typically subsides unless doses are escalated rapidly
• Appetite suppression becomes pronounced (40–60% reduction in typical meal size)
• Food cravings diminish, particularly for calorie-dense foods
• Energy stable if adequate calories are consumed

Week 3–4

• Maximal appetite suppression achieved at higher doses (300+ mcg)
• Hunger ratings decline to 2–3/10 (from baseline 6–8/10)
• Some users report mild injection site reactions (redness, minor bruising) if rotating sites inadequately
• Gastrointestinal motility notably reduced; some constipation possible

Week 5–8

• Peak efficacy window; appetite suppression stable and predictable
• Weight loss accelerates if paired with caloric deficit and resistance training
• Satiety effect lasts 4–6 hours post-injection
• Minimal side effects in most users

Week 9–12

• Appetite suppression may slightly diminish (possible receptor desensitization)
• Some users report return of mild hunger cravings by week 11–12
• Off-cycle planning should begin by week 10

Off-Cycle (Weeks 1–4)

• Day 1–3: Appetite rebound; hunger ratings return toward baseline
• Week 2: Normalization of appetite hormones; hunger stabilizes at new baseline
• Week 3–4: Endogenous appetite regulation fully restored; ready for next cycle

Common Protocol Mistakes

1. Insufficient Titration Jumping from 200 mcg to 500 mcg within 2–3 weeks causes severe nausea and dropout risk. Always titrate in 100 mcg increments over 2-week intervals. The body requires time to acclimate.

2. Inadequate Food Intake on-Cycle PYY suppresses appetite; users may unintentionally create severe caloric deficits (1500–2000 kcal/day) leading to muscle loss, hormonal dysfunction, and fatigue. Intentionally consume high-protein meals even without hunger. Track calories.

3. No Off-Cycle Running PYY continuously beyond 12 weeks increases nausea, triggers receptor downregulation, and reduces subsequent cycle efficacy. The 4-week off-cycle is non-negotiable.

4. Poor Injection Technique Injecting into muscle instead of subcutaneous tissue causes bruising and altered absorption. Injecting at the same site repeatedly causes lipohypertrophy. Always rotate sites and pinch skin to ensure subcutaneous placement.

5. Reconstitution Errors Shaking reconstituted PYY degrades the peptide. Reconstitute gently and store at 2–8°C immediately. Lyophilized powder kept at room temperature degrades rapidly.

6. Timing Inconsistency Administering PYY at variable times (sometimes morning, sometimes afternoon) reduces predictability of appetite suppression. Always inject 30–60 minutes before breakfast for consistent effect.

7. Ignoring Refractory Response Some users expect continuous maximal suppression across all 12 weeks. By weeks 10–12, diminished response is normal. Plan the off-cycle accordingly rather than increasing dose further.

How to Stack with Other Compounds

PYY is fundamentally an appetite suppressant, not an anabolic or performance-enhancing compound. Stacking is primarily relevant for potentiating appetite suppression or offsetting side effects.

Stacking for Enhanced Appetite Suppression

If appetite suppression diminishes by week 9–10 of a PYY cycle (tolerance development), add a complementary satiety agent:

• Glucomannan (soluble fiber): 5 g twice daily with meals. Expands in the stomach, creating mechanical fullness. Synergizes with PYY's neural appetite suppression.
• L-Glutamine: 5–10 g daily. Supports gut barrier function and may enhance satiety signaling.
• Propionate ester (inulin-propionate): 10 g daily. Increases endogenous PYY production, stacking with exogenous PYY for additive effect.

Stacking to Offset Nausea

• Ginger extract: 1–2 g daily. Reduces nausea severity in the first 1–2 weeks without blunting PYY efficacy.
• Ondansetron (prescription, if available): 4–8 mg daily during weeks 1–2 of titration only. Blocks 5-HT3 receptors to reduce PYY-induced nausea.

Stacking to Preserve Muscle Mass

Since PYY creates appetite suppression that may lead to undereating and muscle loss:

• High-protein intake: 1.0–1.2 g per lb bodyweight daily (non-negotiable).
• Resistance training: 3–5 sessions weekly during the cycle to preserve lean mass.
• Creatine monohydrate: 5 g daily. Supports muscle retention and cognitive function independent of PYY.

Compounds NOT to Stack with PYY

• GLP-1 agonists (semaglutide, tirzepatide): Both act via overlapping appetite suppression pathways. Stacking produces excessive nausea and vomiting, increasing adverse event risk. If GLP-1 is being used, defer PYY until after the GLP-1 cycle concludes.
• Stimulants (caffeine, ephedrine): Increase sympathetic tone and can amplify dizziness and lightheadedness secondary to caloric deficit.

Protocol Quick Reference Table

Signs It's Working (Efficacy Markers)

• Reduced meal size: Baseline meals of 800–1000 kcal reduced to 400–600 kcal without effort
• Suppressed food cravings: 50–70% reduction in desire for sweets, fried foods, or snacks